MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3

Histone deacetylases 1–3 (HDAC1, HDAC2, and HDAC3) and their associated corepressor complexes play important roles in regulating chromatin structure and gene transcription. HDAC enzymes are also validated drug targets for oncology and offer promise toward new drugs for neurodegenerative diseases and...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2024-01, Vol.15 (1), p.93-98
Main Authors: Smalley, Joshua P., Cowley, Shaun M., Hodgkinson, James T.
Format: Article
Language:English
Subjects:
Letter
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-a405t-dc60ab3c39ab56870f3704c01d5d1f60d0b4346c6c479924add9861ea44066783
container_end_page 98
container_issue 1
container_start_page 93
container_title ACS medicinal chemistry letters
container_volume 15
creator Smalley, Joshua P.
Cowley, Shaun M.
Hodgkinson, James T.
description Histone deacetylases 1–3 (HDAC1, HDAC2, and HDAC3) and their associated corepressor complexes play important roles in regulating chromatin structure and gene transcription. HDAC enzymes are also validated drug targets for oncology and offer promise toward new drugs for neurodegenerative diseases and cardiovascular diseases. We synthesized four novel heterobifunctional molecules designed to recruit the mouse double minute 2 homologue (MDM2) E3 ligase to degrade HDAC1–3 utilizing the MDM2 inhibitor idasanutlin, known as proteolysis targeting chimeras (PROTACs). Idasanutlin inhibits the MDM2-P53 protein–protein interaction and is in clinical trials. Although two MDM2-recruiting heterobifunctional molecules reduced HDAC1 and HDAC2 abundance with complete selectivity over HDAC3 and reduced HDAC1/2 corepressor components LSD1 and SIN3A, we were surprised to observe that idasanutlin alone was also capable of this effect. This finding suggests an association between the MDM2 E3 ligase and HDAC1/2 corepressor complexes, which could be important for designing future dual/bifunctional HDAC- and MDM2-targeting therapeutics, such as PROTACs.
doi_str_mv 10.1021/acsmedchemlett.3c00449
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10788946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915989293</sourcerecordid><originalsourceid>FETCH-LOGICAL-a405t-dc60ab3c39ab56870f3704c01d5d1f60d0b4346c6c479924add9861ea44066783</originalsourceid><addsrcrecordid>eNqFkV1LHDEUhoO0-NX-BcmlN6snk0w-rmRZ2ypoW8TeFcKZJKsjs8k2yRT67zu6q-iVVwnkeZ8czkvIEYMTBg07RVdWwbv7sBpCrSfcAQhhdsg-M0LPWq3aD6_ue-SglAcAaZSCXbLHddMYJWGf_L4-v27oPFa8S7EvlV56LBjHOvSR3gQ_ulDoxfl8wU4nrBujx-gCxejpIuWwzqGUlOlPzDWGXGg3Vvo91acI_0Q-LnEo4fP2PCS_vn65XVzMrn58u1zMr2YooK0z7yRgxx032LVSK1hyBcIB861nSwkeOsGFdNIJZUwj0HujJQsoBEipND8kZxvveuwetxJizTjYde5XmP_ZhL19-xL7e3uX_loGSmsj5GQ43hpy-jOGUu2qLy4MA8aQxmIbw1qjTWP4hMoN6nIqJYflyz8M7GM39m03dtvNFDx6PeVL7LmMCWg2wCSwD2nMcVrae9b_vXafxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915989293</pqid></control><display><type>article</type><title>MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Smalley, Joshua P. ; Cowley, Shaun M. ; Hodgkinson, James T.</creator><creatorcontrib>Smalley, Joshua P. ; Cowley, Shaun M. ; Hodgkinson, James T.</creatorcontrib><description>Histone deacetylases 1–3 (HDAC1, HDAC2, and HDAC3) and their associated corepressor complexes play important roles in regulating chromatin structure and gene transcription. HDAC enzymes are also validated drug targets for oncology and offer promise toward new drugs for neurodegenerative diseases and cardiovascular diseases. We synthesized four novel heterobifunctional molecules designed to recruit the mouse double minute 2 homologue (MDM2) E3 ligase to degrade HDAC1–3 utilizing the MDM2 inhibitor idasanutlin, known as proteolysis targeting chimeras (PROTACs). Idasanutlin inhibits the MDM2-P53 protein–protein interaction and is in clinical trials. Although two MDM2-recruiting heterobifunctional molecules reduced HDAC1 and HDAC2 abundance with complete selectivity over HDAC3 and reduced HDAC1/2 corepressor components LSD1 and SIN3A, we were surprised to observe that idasanutlin alone was also capable of this effect. This finding suggests an association between the MDM2 E3 ligase and HDAC1/2 corepressor complexes, which could be important for designing future dual/bifunctional HDAC- and MDM2-targeting therapeutics, such as PROTACs.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.3c00449</identifier><identifier>PMID: 38229760</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2024-01, Vol.15 (1), p.93-98</ispartof><rights>2023 The Authors. Published by American Chemical Society</rights><rights>2023 The Authors. Published by American Chemical Society.</rights><rights>2023 The Authors. Published by American Chemical Society 2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a405t-dc60ab3c39ab56870f3704c01d5d1f60d0b4346c6c479924add9861ea44066783</cites><orcidid>0000-0001-9978-7322</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38229760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smalley, Joshua P.</creatorcontrib><creatorcontrib>Cowley, Shaun M.</creatorcontrib><creatorcontrib>Hodgkinson, James T.</creatorcontrib><title>MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Histone deacetylases 1–3 (HDAC1, HDAC2, and HDAC3) and their associated corepressor complexes play important roles in regulating chromatin structure and gene transcription. HDAC enzymes are also validated drug targets for oncology and offer promise toward new drugs for neurodegenerative diseases and cardiovascular diseases. We synthesized four novel heterobifunctional molecules designed to recruit the mouse double minute 2 homologue (MDM2) E3 ligase to degrade HDAC1–3 utilizing the MDM2 inhibitor idasanutlin, known as proteolysis targeting chimeras (PROTACs). Idasanutlin inhibits the MDM2-P53 protein–protein interaction and is in clinical trials. Although two MDM2-recruiting heterobifunctional molecules reduced HDAC1 and HDAC2 abundance with complete selectivity over HDAC3 and reduced HDAC1/2 corepressor components LSD1 and SIN3A, we were surprised to observe that idasanutlin alone was also capable of this effect. This finding suggests an association between the MDM2 E3 ligase and HDAC1/2 corepressor complexes, which could be important for designing future dual/bifunctional HDAC- and MDM2-targeting therapeutics, such as PROTACs.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkV1LHDEUhoO0-NX-BcmlN6snk0w-rmRZ2ypoW8TeFcKZJKsjs8k2yRT67zu6q-iVVwnkeZ8czkvIEYMTBg07RVdWwbv7sBpCrSfcAQhhdsg-M0LPWq3aD6_ue-SglAcAaZSCXbLHddMYJWGf_L4-v27oPFa8S7EvlV56LBjHOvSR3gQ_ulDoxfl8wU4nrBujx-gCxejpIuWwzqGUlOlPzDWGXGg3Vvo91acI_0Q-LnEo4fP2PCS_vn65XVzMrn58u1zMr2YooK0z7yRgxx032LVSK1hyBcIB861nSwkeOsGFdNIJZUwj0HujJQsoBEipND8kZxvveuwetxJizTjYde5XmP_ZhL19-xL7e3uX_loGSmsj5GQ43hpy-jOGUu2qLy4MA8aQxmIbw1qjTWP4hMoN6nIqJYflyz8M7GM39m03dtvNFDx6PeVL7LmMCWg2wCSwD2nMcVrae9b_vXafxw</recordid><startdate>20240111</startdate><enddate>20240111</enddate><creator>Smalley, Joshua P.</creator><creator>Cowley, Shaun M.</creator><creator>Hodgkinson, James T.</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9978-7322</orcidid></search><sort><creationdate>20240111</creationdate><title>MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3</title><author>Smalley, Joshua P. ; Cowley, Shaun M. ; Hodgkinson, James T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a405t-dc60ab3c39ab56870f3704c01d5d1f60d0b4346c6c479924add9861ea44066783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smalley, Joshua P.</creatorcontrib><creatorcontrib>Cowley, Shaun M.</creatorcontrib><creatorcontrib>Hodgkinson, James T.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smalley, Joshua P.</au><au>Cowley, Shaun M.</au><au>Hodgkinson, James T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2024-01-11</date><risdate>2024</risdate><volume>15</volume><issue>1</issue><spage>93</spage><epage>98</epage><pages>93-98</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Histone deacetylases 1–3 (HDAC1, HDAC2, and HDAC3) and their associated corepressor complexes play important roles in regulating chromatin structure and gene transcription. HDAC enzymes are also validated drug targets for oncology and offer promise toward new drugs for neurodegenerative diseases and cardiovascular diseases. We synthesized four novel heterobifunctional molecules designed to recruit the mouse double minute 2 homologue (MDM2) E3 ligase to degrade HDAC1–3 utilizing the MDM2 inhibitor idasanutlin, known as proteolysis targeting chimeras (PROTACs). Idasanutlin inhibits the MDM2-P53 protein–protein interaction and is in clinical trials. Although two MDM2-recruiting heterobifunctional molecules reduced HDAC1 and HDAC2 abundance with complete selectivity over HDAC3 and reduced HDAC1/2 corepressor components LSD1 and SIN3A, we were surprised to observe that idasanutlin alone was also capable of this effect. This finding suggests an association between the MDM2 E3 ligase and HDAC1/2 corepressor complexes, which could be important for designing future dual/bifunctional HDAC- and MDM2-targeting therapeutics, such as PROTACs.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>38229760</pmid><doi>10.1021/acsmedchemlett.3c00449</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9978-7322</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1948-5875
ispartof ACS medicinal chemistry letters, 2024-01, Vol.15 (1), p.93-98
issn 1948-5875
1948-5875
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10788946
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Letter
title MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A26%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MDM2%20Antagonist%20Idasanutlin%20Reduces%20HDAC1/2%20Abundance%20and%20Corepressor%20Partners%20but%20Not%20HDAC3&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Smalley,%20Joshua%20P.&rft.date=2024-01-11&rft.volume=15&rft.issue=1&rft.spage=93&rft.epage=98&rft.pages=93-98&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.3c00449&rft_dat=%3Cproquest_pubme%3E2915989293%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a405t-dc60ab3c39ab56870f3704c01d5d1f60d0b4346c6c479924add9861ea44066783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2915989293&rft_id=info:pmid/38229760&rfr_iscdi=true